Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report published on Friday, Marketbeat reports. The brokerage currently has a $400.00 price objective on the biopharmaceutical company’s stock.

ALNY has been the subject of several other research reports. UBS Group increased their target price on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Stifel Nicolaus increased their target price on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Chardan Capital restated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Needham & Company LLC restated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 10th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 10th. Six analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $286.82.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $295.93 on Friday. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The firm has a market capitalization of $37.43 billion, a price-to-earnings ratio of -110.42 and a beta of 0.39. The business has a 50 day simple moving average of $271.82 and a two-hundred day simple moving average of $217.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same period in the prior year, the company posted ($2.21) EPS. The firm’s revenue was up 107.0% on a year-over-year basis. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post -2.73 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,398 shares of company stock worth $13,595,460 in the last ninety days. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its holdings in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the period. Ashton Thomas Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $26,000. Altitude Crest Partners Inc. bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $30,000. Friedenthal Financial bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $51,000. Finally, Meeder Asset Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 1,237.5% during the second quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 297 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.